MBRX — Moleculin Biotech Share Price
0.000.00%
Last trade - 00:00- $14.42m
- $10.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.41 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -238.92% | ||
| Return on Equity | -135.8% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 28th, 2015
- Public Since
- June 2nd, 2016
- No. of Shareholders
- 139
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 14,000,494
- Address
- 5300 Memorial Dr Ste 950, HOUSTON, 77007-8274
- Web
- https://moleculin.com/
- Phone
- +1 7133005160
- Contact
- Jenene Thomas
- Auditors
- Grant Thornton LLP
Upcoming Events for MBRX
Q2 2025 Moleculin Biotech Inc Earnings Release
Moleculin Biotech Inc Annual Shareholders Meeting
Similar to MBRX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Moleculin Biotech share price?
As of Today at 22:07 UTC, shares in Moleculin Biotech are trading at $1.03. This share price information is delayed by 15 minutes.
How has the Moleculin Biotech share price performed this year?
Shares in Moleculin Biotech last closed at $1.03 and the price had moved by -80% over the past 365 days. In terms of relative price strength the Moleculin Biotech share price has underperformed the S&P500 Index by -81.97% over the past year.
What are the analyst and broker recommendations for Moleculin Biotech?
The overall consensus recommendation for Moleculin Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Moleculin Biotech dividend yield?
Moleculin Biotech does not currently pay a dividend.
Does Moleculin Biotech pay a dividend?
Moleculin Biotech does not currently pay a dividend.
When does Moleculin Biotech next pay dividends?
Moleculin Biotech does not currently pay a dividend.
How do I buy Moleculin Biotech shares?
To buy shares in Moleculin Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Moleculin Biotech?
As of the previous close price of $1.03, shares in Moleculin Biotech had a market capitalisation of $14.42m.
Where are Moleculin Biotech shares listed?
Here are the trading details for Moleculin Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MBRX
What kind of share is Moleculin Biotech?
Based on an overall assessment of its quality, value and momentum Moleculin Biotech is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Moleculin Biotech share price forecast for 2025?
The analyst consensus target price for shares in Moleculin Biotech is $10.67. That is 935.92% above the last closing price of $1.03.
Analysts covering Moleculin Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$1.68 for the next financial year.
Find out moreWhat is the trend in the Moleculin Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moleculin Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -57.77%.
As of the last closing price of $1.03, shares in Moleculin Biotech were trading -48.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Moleculin Biotech PE Ratio?
The Moleculin Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Moleculin Biotech?
We do not have data on Moleculin Biotech's directors